Abstract
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B(®)). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic
-
Adult
-
Aged
-
Antibodies, Viral / blood
-
Antibodies, Viral / immunology
-
Double-Blind Method
-
Drug-Related Side Effects and Adverse Reactions
-
Female
-
Hepatitis B / immunology
-
Hepatitis B / prevention & control*
-
Hepatitis B / virology
-
Hepatitis B Surface Antigens / genetics
-
Hepatitis B Surface Antigens / immunology
-
Hepatitis B Vaccines / adverse effects
-
Hepatitis B Vaccines / genetics
-
Hepatitis B Vaccines / immunology*
-
Hepatitis B virus / immunology*
-
Humans
-
Immunity, Humoral
-
Male
-
Middle Aged
-
Oligodeoxyribonucleotides / genetics
-
Oligodeoxyribonucleotides / immunology
-
Placebos
-
Toll-Like Receptor 9 / agonists
-
Toll-Like Receptor 9 / genetics
-
Toll-Like Receptor 9 / immunology
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Hepatitis B Surface Antigens
-
Hepatitis B Vaccines
-
Oligodeoxyribonucleotides
-
Placebos
-
Toll-Like Receptor 9
-
1018 oligonucleotide